title: Low percentage of CD24hiCD27⁺CD19⁺ B cells decelerates gastric cancer progression in XELOX-treated patients.
abstract: The XELOX regimen (capecitabine plus oxaliplatin) has been demonstrated as first-line chemotherapy for gastric cancer in China. However, the efficacy of XELOX varies in individuals. Some evidences indicate that the variable efficacy might be related to the distinct immune status not only in the tumor site but also in the systemic immune system, and further investigation is required. In this study, we collected 32 PBMC samples from 16 XELOX-treated patients with gastric cancer and analyzed the patterns of immune cells. At the end point, the proportion of CD24(hi)CD27(+)CD19(+) B cells in patients without progression revealed a significant decrease compared with that in patients with progression, but not other immune cells, such as T cells and NK cells. Furthermore, CD19(+) B cells were more sensitive to capecitabine plus oxaliplatin stimulation in vitro than other immune cells, displaying higher frequency of apoptosis in a dose-dependent way. Thus, our results suggested that the outcomes of XELOX chemotherapy were inversely correlated with peripheral B cell subsets, which might provide a more convenient method to predict gastric cancer progression of XELOX-treated patients.
authors.affiliation: Department of Immunology, School of Basic Medical Sciences, Biotherapy Research Center, Fudan University, Shanghai, China.
authors.forename: Jiao
authors.initials: J
authors.lastname: Yang
authors.affiliation: Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.affiliation: Department of Immunology, School of Basic Medical Sciences, Biotherapy Research Center, Fudan University, Shanghai, China.
authors.forename: Feifei
authors.initials: F
authors.lastname: Luo
authors.affiliation: Department of Biostatistics, Fudan University, Shanghai, China.
authors.forename: Naiqing
authors.initials: N
authors.lastname: Zhao
authors.affiliation: Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
authors.forename: Wen
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Immunology, School of Basic Medical Sciences, Biotherapy Research Center, Fudan University, Shanghai, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Zhang
authors.affiliation: Department of Immunology, School of Basic Medical Sciences, Biotherapy Research Center, Fudan University, Shanghai, China.
authors.forename: Jiawen
authors.initials: J
authors.lastname: Qian
authors.affiliation: Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
authors.forename: Yiwei
authors.initials: Y
authors.lastname: Yu
authors.affiliation: Department of Immunology, School of Basic Medical Sciences, Biotherapy Research Center, Fudan University, Shanghai, China.
authors.forename: Xiujuan
authors.initials: X
authors.lastname: Zheng
authors.affiliation: Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Feng
authors.affiliation: Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address: liu.tianshu@zs-hospital.sh.cn.
authors.forename: Tianshu
authors.initials: T
authors.lastname: Liu
authors.affiliation: Department of Immunology, School of Basic Medical Sciences, Biotherapy Research Center, Fudan University, Shanghai, China. Electronic address: yiwei_chu@126.com.
authors.forename: Yiwei
authors.initials: Y
authors.lastname: Chu
mesh_terms: D000328:Adult; D000368:Aged; D018941:Antigens, CD19 / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D017209:Apoptosis / Q000187:drug effects; D016175:B-Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D054316:Biomarkers, Pharmacological / Q000378:metabolism; D051927:CD24 Antigen / Q000378:metabolism; D000069287:Capecitabine; D002277:Carcinoma / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D002681:China; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010071:Oxaloacetates; D011379:Prognosis; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D016896:Treatment Outcome; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000378:metabolism
chemical_list: D018941:Antigens, CD19; D054316:Biomarkers, Pharmacological; D051927:CD24 Antigen; D010071:Oxaloacetates; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil
keywords: B cells; Gastric cancer; XELOX chemotherapy